Abstract
Gliomas are the most common primary brain cancers. In recent years, IDH mutation and 1p/19q codeletion have been suggested as biomarkers for the diagnosis, treatment and prognosis of gliomas. However, these biomarkers are only effective for a part of glioma patients and thus more biomarkers are still emergently needed. Recently, an electrochemical communication between normal neurons and glioma cells by neuro-glioma synapse has been reported. Moreover, it was discovered that breast-to-brain metastasis tumor cells have pseudo synapses with neurons and these synapses were indicated to promote tumor progression and metastasis. Based on the above observations, we first curated a panel of 66 SA genes and then proposed a metric, SA score, to quantify the synapseness for each sample of 12 glioma gene expression datasets from TCGA, CGGA, and GEO. Strikingly, SA score showed excellent predictive ability for the prognosis, diagnosis, and grading of gliomas. Moreover, being compared with the two established biomarkers, IDH mutation and 1p/19q codeletion, SA score was demonstrated independent and better predictive performance. In conclusion, this study revealed that SA genes contribute to glioma formation and development, and proposed a quantitative method, SA score, as an efficient biomarker for monitoring gliomas.
Introduction
Gliomas represent the most prevalent primary brain malignancies, and their clinical management relies heavily on molecular biomarkers. Currently, clinicians utilize IDH mutations and 1p/19q codeletions to guide treatment and predict outcomes. However, these markers are only present or effective in specific subsets of patients, leaving a significant gap in monitoring the broader glioma population.
Recent "neuro-cancer" research has revealed that glioma cells can form functional, electrochemical synapses with healthy neurons. While these "neuro-glioma synapses" were initially thought to simply promote tumor growth, this study investigates whether the genetic machinery behind these connections—synapse assembly (SA) genes—can be harnessed as a reliable diagnostic and prognostic tool.
Methods
The researchers developed a bioinformatics-driven approach to quantify "synapseness" in tumor samples:
- Gene Selection: A list of 66 genes specifically involved in the "positive regulation of synapse assembly" was curated from the Gene Ontology database.
- SA Score Calculation: Using single sample Gene Set Enrichment Analysis (ssGSEA), raw RNA sequencing data was transformed into a single "SA score" for every individual patient sample.
- Validation: This scoring system was applied to over 3,000 samples across 12 different datasets, including TCGA (The Cancer Genome Atlas), CGGA (Chinese Glioma Genome Atlas), and GEO (Gene Expression Omnibus) to ensure robustness.
Key Results
The Survival Paradox
Previous studies suggested that neuro-glioma synapses help tumors grow. Surprisingly, this research found that patients with higher SA scores (indicating more synaptic gene activity) actually had significantly longer overall survival across all major datasets.
Diagnostic and Grading Precision
The SA score serves as an excellent diagnostic tool, distinguishing between glioma and normal brain tissue with high accuracy (AUCs ranging from 0.91 to 0.99). Furthermore, SA scores were significantly lower in higher-grade gliomas (WHO Grade IV/GBM) compared to lower-grade ones (Grades II and III), suggesting that loss of synaptic gene expression correlates with tumor progression.
Independence from Existing Markers
The SA score remained a significant predictor even after adjusting for WHO grade, IDH status, and 1p/19q status. This suggests it captures a unique biological dimension of the disease that current clinical tests miss. In several head-to-head comparisons, the SA score outperformed IDH mutation status in predicting survival.
Discussion and Biological Mechanism
The authors propose a biological mechanism for these findings involving the balance between the cAMP and NF-κB signaling pathways. High SA scores correlate with the activation of the cAMP signaling pathway (associated with synaptic plasticity) and the suppression of the NF-κB pathway (associated with inflammation and tumor immune escape). Essentially, "more synaptic" tumors might be less aggressive because they are less effective at evading the immune system.
While the statistical evidence is robust across 3,000+ samples, the study is retrospective. Prospective clinical trials are needed to validate the SA score in a real-world setting. Future work could investigate whether drugs targeting these pathways could mimic the "high SA score" state to improve patient outcomes.
Conclusion
This study reveals that SA genes contribute significantly to glioma development and proposes the SA score as an efficient, independent biomarker for monitoring gliomas. By quantifying the "synapseness" of a tumor, clinicians may gain deeper insights into its clinical behavior and prognosis.
Summary updated